The Series A round was led by Khosla Ventures, an existing investor with the participation of new investors including Data Collective (DCVC), Greenbox Venture Partners, Minneapolis Heart Institute Ventures and Georges Harik. The proceeds will be used to continue clinical validation, accelerate technological development and bring Bay Labs products to the U. Oh, S Market: Market In addition, Ben Ling, Managing Partner at Khosla Ventures, and Armen Vidian, Managing Partner at DCCV, will join the Board of Directors of Bay Labs.
Physicians today need imaging studies that provide high-quality diagnostic capabilities, no matter where the patient is, from inpatient hospital settings to outpatient settings and care settings. Bay Labs uses AI for cardiovascular imaging to help diagnose and manage heart disease. Echocardiographic examination (ultrasound images of the heart) is a gateway to cardiovascular disease diagnosis and a key to disease management and appropriate timing of intervention. The company’s deep learning technology, a type of AI algorithm, is designed to help medical professionals of all skill levels perform and interpret echocardiograms and can improve the treatment of heart disease. Bay Labs has partnered with the Minneapolis Heart Institute and Allina Health, Northwestern Medicine, Duke University School of Medicine, and cardiologists at Stanford University to develop, test and validate deep-learning echocardiography algorithms.
“We are pleased with the continued support from our existing investor Khosla Ventures and welcome our new investors-all of whom share our vision of how deep learning technology can address two key challenges in diagnostic cardiology: the acquisition and interpretation of echocardiograms,” said Charles Cadieu, co-founder and CEO of Bay Labs. “We welcome Ben Ling and Armen Vidian as board members and look forward to their strategic contributions to our efforts to enable providers of high-quality cardiac imaging to improve patient care. “That’s right.
“The unique use of ultrasound AI by Bay Labs has the potential to enable medical professionals to provide patients with faster and better care,” said Ben Ling, general partner at Khosla Ventures. “We’re excited to increase our investment in the Bay Labs to revolutionize ultrasound. “That’s right.
“We are impressed by the strength of the Bay Labs AI engine to deliver consistently high-quality ultrasound images and key data to physicians when they need it most-at the point of care, and we are particularly excited to see such early enthusiasm from some of the world’s leading physicians,” said Armen Vidian, DCVC’s operating partner. “We see tremendous potential for this smart, data-rich technology to have an impact on how and when physicians direct patient care to dramatically improve outcomes. “That’s right.
About Bay Laboratories
Bay Labs is a San Francisco-based privately held company focused on improving quality, value and access to medical imaging through a combination of deep learning and ultrasound. Founded in 2013, Bay Labs applies artificial intelligence to cardiovascular imaging, and its deep learning technology is designed to help medical professionals of all skill levels perform and interpret high-quality echocardiography to ultimately benefit their patients. Bay Labs products are for investigational use only and are not currently available for sale. For more information on Bay Labs, please visit www. Bailabs, Io/Oh
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Bay%20Labs/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
